Analytical Chemistry and Pharmacology Core Facility The goal of this core is to support the translational development of small molecule and nanoparticle anticancer agents via analytical chemistry and pharmacologic infrastructure and methodologies. The expansion of the MolecularTherapeutics Program, development of preclinical models used to evaluate anticancer agents and the opening of new North Carolina Cancer Hospital's Clinical Trials Unit created the demand for applied pharmacology services. The recruitment of Dr. Zamboni and the substantial investment of cancer center institutional funds launched the core and its operations. This new core is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab (opened in March'09) and the UNC GLP Bioanalytical Facility (will open in Feb'10). The technologies and resources offered by this core were not previously available at UNC. Moreover, the UNC GLP Bioanalytical Facility is one of the few such GLP labs that exist in an academic center. The core resources will expand researchers'horizons and funding by providing outstanding expertise in performing analytical and pharmacology studies, providing the highest quality of data and performing these studies in a cost effective manner. The core's sen/ices consist of: analytical studies at GLP and non-GLP levels;development of drug formulations;development and validation of analytical assays In biological matrices;sample analysis;pharmacokinetic and pharmacodynamic data analysis;and specialized methods for nanoparticle pharmacology. An example of this is the collaboration with Drs. Sharpless, Collichio and Ollila, where we are currently evaluating the factors affecting the tumor delivery of anticancer agents in xenograft and genetically engineered mouse models (GEMM) of melanoma and in patients with cutaneous melanoma. Future plans are to expand the research of UNC LCCC members and use the resources of this core to recruit novel anticancer agents to UNC. The core requests $160,846, representing 15% of its operating costs;Cancer Center members constitute 96% of the core's users. This new core will be a tremendous asset to the center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594170
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$209,478
Indirect Cost
$66,183
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Schaefer, Kristina N; Bonello, Teresa T; Zhang, Shiping et al. (2018) Supramolecular assembly of the beta-catenin destruction complex and the effect of Wnt signaling on its localization, molecular size, and activity in vivo. PLoS Genet 14:e1007339
Zuze, Takondwa; Painschab, Matthew S; Seguin, Ryan et al. (2018) Plasmablastic lymphoma in Malawi. Infect Agent Cancer 13:22
Wang, Jeremy R; Holt, James; McMillan, Leonard et al. (2018) FMLRC: Hybrid long read error correction using an FM-index. BMC Bioinformatics 19:50
Lee, Janie M; Abraham, Linn; Lam, Diana L et al. (2018) Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography. J Clin Oncol 36:2070-2077
Shen, Hui; Shih, Juliann; Hollern, Daniel P et al. (2018) Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep 23:3392-3406
Shao, Wenwei; Chen, Xiaojing; Samulski, Richard J et al. (2018) Inhibition of antigen presentation during AAV gene therapy using virus peptides. Hum Mol Genet 27:601-613
Gao, Yanzhe; Kardos, Jordan; Yang, Yang et al. (2018) The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. Sci Rep 8:15304
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Bonacci, Thomas; Suzuki, Aussie; Grant, Gavin D et al. (2018) Cezanne/OTUD7B is a cell cycle-regulated deubiquitinase that antagonizes the degradation of APC/C substrates. EMBO J 37:
Zhang, Zhi-Min; Lu, Rui; Wang, Pengcheng et al. (2018) Structural basis for DNMT3A-mediated de novo DNA methylation. Nature 554:387-391

Showing the most recent 10 out of 1525 publications